Evidence map›Paper›PMID 38730087›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Radiolabelling and preclinical characterisation of [

Zhipeng Cao, Christian Werner Wichmann, Ingrid Julienne Georgette Burvenich, Laura Danielle Osellame, Nancy Guo, Angela Rigopoulos, Graeme Joseph O'Keefe, Fiona Elizabeth Scott, Nirmal Lorensuhewa, Kevin Patrick Lynch and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Evaluation of albumin-binding PD-L1-targeted VHH for PET imaging in colorectal cancer.American journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Article
  6. Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) withEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  7. Nuclear Imaging of Bispecific Antibodies on the Rise.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhipeng Cao *Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Christian Werner Wichmann *Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Ingrid Julienne Georgette Burvenich *Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Laura Danielle OsellameTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Nancy GuoTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Angela RigopoulosTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Graeme Joseph O'KeefeDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
Fiona Elizabeth ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
Nirmal LorensuhewaAntengene Biologics Limited, Shanghai, China.
Kevin Patrick LynchAntengene Biologics Limited, Shanghai, China.
Andrew Mark ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. Andrew.Scott@onjcri.org.au.ORCID 0000-0002-6656-295X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeATG-101, a bispecific antibody that simultaneously targets the immune checkpoint PD-L1 and the costimulatory receptor 4-1BB, activates exhausted T cells upon PD-L1 crosslinking. Previous studies demonstrated promising anti-tumour efficacy of ATG-101 in preclinical models. Here, we labelled ATG-101 with

methodsATG-101, anti-PD-L1, and an isotype control were conjugated with p-SCN-Deferoxamine (Df). The Df-conjugated antibodies were radiolabelled with

resultsThe Df-conjugation and [

conclusion[

Indexed as

Antibodies, BispecificB7-H1 AntigenZirconiumAnimalsCell Line, TumorDeferoxamineFemaleHumansIsothiocyanatesIsotope LabelingMiceMice, Inbred BALB CPositron-Emission TomographyRadioisotopesTissue Distribution4-isothiocyanatobenzyl-desferrioxamineAntibodies, BispecificB7-H1 AntigenDeferoxamineIsothiocyanatesRadioisotopesZirconiumZirconium-894-1BBATG-101PD-L1PETZirconium-89

Identifiers

PMID38730087
PMCPMC11368977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.